Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
1(17%)
Results Posted
0%(0 trials)
Terminated
1(17%)

Phase Distribution

Ph not_applicable
1
17%
Ph phase_3
2
33%
Ph phase_4
1
17%
Ph phase_2
2
33%

Phase Distribution

0

Early Stage

2

Mid Stage

3

Late Stage

Phase Distribution6 total trials
Phase 2Efficacy & side effects
2(33.3%)
Phase 3Large-scale testing
2(33.3%)
Phase 4Post-market surveillance
1(16.7%)
N/ANon-phased studies
1(16.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

1

trials recruiting

Total Trials

6

all time

Status Distribution
Active(3)
Completed(2)
Terminated(1)

Detailed Status

Completed2
Recruiting1
Terminated1
Not yet recruiting1
Enrolling by invitation1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
1
Success Rate
66.7%
Most Advanced
Phase 4

Trials by Phase

Phase 22 (33.3%)
Phase 32 (33.3%)
Phase 41 (16.7%)
N/A1 (16.7%)

Trials by Status

completed233%
recruiting117%
terminated117%
not_yet_recruiting117%
enrolling_by_invitation117%

Recent Activity

1 active trials
Showing 5 of 6
completednot_applicable

Bioequivalence Study of EMPAGLIFLOZIN (25 mg Tablets) vs. JARDIANCE® (25 mg Tablets), in Healthy Research Subjects, Under Fasting Conditions

NCT07479108
completedphase_4

The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity

NCT07120828
recruitingphase_2

Effect of Empagliflozin on Metabolic Outcomes in Adults Living With HIV Receiving Dolutegravir-Based Therapy

NCT07336797
not_yet_recruitingphase_2

Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin

NCT07175051
enrolling_by_invitationphase_3

Treating the Metabolic Syndrome With a Sodium-glucose Cotransporter-2 Inhibitor

NCT07065357
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT07479108Not Applicable

Bioequivalence Study of EMPAGLIFLOZIN (25 mg Tablets) vs. JARDIANCE® (25 mg Tablets), in Healthy Research Subjects, Under Fasting Conditions

Completed
NCT07120828Phase 4

The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity

Completed
NCT07336797Phase 2

Effect of Empagliflozin on Metabolic Outcomes in Adults Living With HIV Receiving Dolutegravir-Based Therapy

Recruiting
NCT07175051Phase 2

Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin

Not Yet Recruiting
NCT07065357Phase 3

Treating the Metabolic Syndrome With a Sodium-glucose Cotransporter-2 Inhibitor

Enrolling By Invitation
NCT03060980Phase 3

Comparison of Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and Glimepiride as add-on Metformin

Terminated

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6